• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

News

Article

Interview Intersection: Expert Interviews From November 2024

Key Takeaways

  • Rademikibart shows superior IL-4Rα binding affinity, enhancing treatment efficacy in atopic dermatitis and asthma.
  • Benzene contamination in benzoyl peroxide raises safety concerns, prompting calls for stricter regulations and safer alternatives.
SHOW MORE

Dermatology Times is recapping our top expert interviews from the month of November.

November Interview Intersection logo

Rademikibart Differentiates From Dupilumab With Optimized IL-4Rα Inhibition and Enhanced Binding Stability

Christopher Bunick, MD, PhD, highlights rademikibart's next-generation efficacy, showing stronger IL-4Rα binding affinity in atopic dermatitis and asthma.

Benzene Concerns in Benzoyl Peroxide Spark Calls for Safer Acne Treatment Standards

As news of benzene contamination in benzoyl peroxide products continues to raise safety discussions, Steve Xu, MD, MSc, advocates for stricter regulations, increased research, and the consideration of safer acne treatment alternatives.

SCAN Project Empowers Cosmetologists in Early Skin Cancer Detection

Bree Vanleeuwen, PA-C, and Jim Sutton, PA-C, discussed the Skin Cancer Awareness project—a unique initiative to train cosmetologists and hairdressers to recognize suspicious skin lesions and refer clients for dermatologic evaluation.

Kicking Off Elevate-Derm West With Eileen Cheever, MPAS, PA-C

Cheever shared with Dermatology Times her excitement for educational opportunities, networking, and presentations from experts in the specialty.

“Is AI Coming for My Job?”: Familiarizing Clinicians with AI Tools and Their Role in Dermatology

In a session at Elevate-Derm West, Cheever presented on the utilization of AI within dermatology to optimize patient communication and diversify research.

Topics and Pearls

  • Disease states such as acne, alopecia, asthma, atopic dermatitis, contact dermatitis, eczema, hidradenitis suppurativa, hyperhidrosis, hyperpigmentation, itch, nail disorders, pemphigoid gestationis, polymorphic eruption, postpartum skin conditions, prurigo nodularis, psoriasis, rosacea, and skin cancer
  • Pearls for emerging therapeutics
  • Conference data and pearls

Exploring Diet and New Treatments for Hidradenitis Suppurativa

From diet recommendations to biologic advancements, Jennifer Hsiao, MD, covered essential updates for treating patients with HS.

Updates on the Latest Cosmetic Treatments in Medical Care

Affordable at-home treatments, including microneedling and benzoyl peroxide, were top pearls at Chilukuri's Elevate-Derm session.

Latest Laser and Skincare Innovations for Hyperpigmentation with Suneel Chilukuri, MD, FAAD, FACMS

Chilukuri shared that 2 new sunscreen ingredients, physalis angulata and pycnogenol, can prevent heat-induced pigmentation, offering new options for patients.

Ashfaq Marghoob, MD: Identifying Dermoscopic Patterns in Facial, Palmoplantar, Nail, and Mucosal Lesions

Marghoob shares key dermoscopic features to help clinicians identify benign vs malignant lesions on various locations of the body.

Navigating Skin Disease Treatment During Pregnancy

Murase noted small molecule treatments, like JAK inhibitors, remain unsafe for pregnant women.

Pediatric Dermatology Essentials: Lisa Swanson, MD, on Treating Young Patients with Confidence

Swanson shared practical tips from her Elevate-Derm West sessions, empowering clinicians with new strategies for pediatric skin care.

Jenny Murase, MD: Emerging Therapies Bring Hope to Patients with Persistent Itch

At Elevate-Derm West, Murase shared promising results in treating severe itch with emerging therapies, offering hope for patients with few options.

Improving Hyperhidrosis Treatment: The Role of IHhS

David M. Pariser, MD, FACP, FAAD, secretary and a founding board member of the International Hyperhidrosis Society, discussed the latest in hyperhidrosis research and the organization’s commitment to helping clinicians treat the condition.

"Baby Bumps": Jenny Murase, MD, on Dermatoses During Pregnancy

Murase identifies 4 main pregnancy dermatoses—atopic eruption, polymorphic eruption, extrahepatic cholestasis, and pemphigoid gestationis—as "baby bumps."

Jenny Murase, MD: Providing Dermatologic Support in Postpartum Care

Murase discussed safe dermatologic treatments during lactation, especially for chronic conditions needing biologics.

Renata Block, MMS, PA-C, Highlights SDPA Fall Sessions

Block emphasized the importance of breakout sessions geared toward varying levels of experience—beginner, intermediate, and advanced.

Matthew Zirwas, MD: Cutting-Edge Advances in Atopic Dermatitis and Itch Management

Zirwas presented 2 sessions at SDPA on innovative care strategies for patients with AD and other itch-related diseases.

Empowering Dermatology PAs Through Education and Career Support

Michael Rubio, PA-C, previews the transformative programming and career-focused initiatives at this year’s Society of Dermatology Physician Associates Fall Conference in Las Vegas.

Derm PAs Look to Give Back: Volunteering at the Sun Bus

Dermatology physician associates via DPAF conduct skin checks at the Sun Bus during the Fall Conference.

From Clinic to Industry: Insights Into the MSL Role and PA Advocacy

At the 2024 SDPA Fall Conference, Sara Wilchowski, DMSc, MPAS, PA-C, highlighted the challenges and rewards of transitioning to industry roles, the impact of “Insta-Tok” on patient care, and the evolving landscape of dermatology.

Advancing Nail Disorder Care by Bridging Podiatry and Dermatology

At the 2024 SDPA Fall Conference, Tracey Vlahovic, DPM, highlighted the need for interdisciplinary collaboration in nail disorder management, underscoring the importance of mutual learning between podiatry and dermatology.

Jane Mast, PhD, DMSc, MPAS: The 2024 Joe Monroe Lifetime Achievement Award Recipient

Jane Mast, PhD, DMSc, MPAS, shares her thoughts on the award, being a Derm PA, and dermatology.

Collaborating for Better Care: SDPA's Role in Advancing Dermatology

At the 2024 SDPA Fall Conference, Renata Block, MMS, PA-C, emphasized the power of membership, tailored education, interdisciplinary collaboration, and advocacy in shaping the future of dermatology to improve patient outcomes.

“Don’t Touch This”: Contact Dermatitis Insights and Updates from Matthew Zirwas, MD

Zirwas spoke with Dermatology Times to share the top clinical pearls and key takeaways from his discussion on contact dermatitis.

Shanna Miranti, MPAS, PA-C, Shares Expert Acne and Pediatric Dermatology Insights

At the SDPA Fall Conference, Miranti emphasized the importance of targeted, comprehensive acne therapies and inspired attendees to embrace pediatric dermatology as a rewarding subspecialty.

Advocating for Innovation and Education in Acne Care

At the 2024 SDPA Fall Conference, Hilary Baldwin, MD, highlighted the superiority of branded acne therapies, the necessity of tailored regimens, and the value of structured PA education.

Advances and Challenges in Rosacea Treatment: Insights From Hilary Baldwin, MD

At the 2024 SDPA Fall Conference, Hilary Baldwin, MD, highlighted innovative strategies for managing complex rosacea cases, the importance of combination approaches, and a slowing treatment pipeline.

Reviewing Multiple Subtypes of CHE and Delgocitinib as a Pan-JAK Inhibitor

Christopher Bunick, MD, PhD, discusses the multifactorial nature of chronic hand eczema, the burden of severe symptoms, and how delgocitinib restores skin integrity by targeting JAK/STAT pathways.

Jeff Stark, MD: Insights on the Approval of Bimekizumab for HS

The pivotal BE HEARD trials demonstrated bimekizumab’s efficacy, showing meaningful improvements over placebo in HS patients.

Advances in HS treatment with Chris Sayed, MD

Unlike previous therapies, bimekizumab has shown continued efficacy at 48 and 96 weeks, offering long-term benefits to HS patients.

Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.

Related Videos
infectious disease
© 2024 MJH Life Sciences

All rights reserved.